Stock listing
Annexon, Inc.
Selected listing: ANNX · NASDAQ · USD · US
Annexon, Inc. (NASDAQ:ANNX), Health Technology. Latest release Sep 24, 2026: Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3…
- Ticker
- NASDAQ:ANNX
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
About Annexon, Inc.
Annexon, Inc. is a public company traded under the ticker ANNX in the American market. Annexon focuses on developing therapies for neurodegenerative diseases and other serious conditions.
Latest news from Annexon, Inc.
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
September 24, 2026
Annexon to Participate in Upcoming September Investor Conferences
September 2, 2026
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
August 12, 2026
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
August 12, 2026
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
August 10, 2026
Events
Replays
Annexon, Inc. (ANNX) Q2 2026 Earnings Call
Wed, Aug 12, 2026 · 08:00 AM ET
Watch